Andrew Lowy
UCSD · University of California, San Diego
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Andrew Lowy as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:26 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT06639724 · Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic CancerUniversity of California, San Diego · recruiting · Pancreatic Ductal Adenocarcinoma (PDAC) · study chair
- Ph2NCT03697564 · Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic CancerHitendra Patel · completed · Pancreatic Cancer Stage IV · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:26 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 3 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Defining the Role of MICAL2 in KRAS Mediated Pancreatic Duct NeoplasiaR01CA309448 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2026 · $643,013 awarded in 2026Same name and institution; not confirmed by an ID
- Full Project 1: Defining Mechanisms of MICAL-dependent Pancreatic Cancer Cell MigrationU54CA285115 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2023 to 2025 · $179,042 awarded in 2025Same name and institution; not confirmed by an ID
- CDK4/6 inhibition: a novel therapeutic strategy for GNAS-mutant gastrointestinal malignanciesR21CA273974 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2022 to 2023 · $217,163 awarded in 2023Same name and institution; not confirmed by an ID
- Targeting the MICAL2 signaling axis in pancreatic cancerR21CA273973 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2022 to 2023 · $217,163 awarded in 2023Same name and institution; not confirmed by an ID
- RON Receptor in Pancreatic Cancer Biology and TherapyR01CA155620 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2011 to 2021 · $306,943 awarded in 2021Same name and institution; not confirmed by an ID
- Musashi-mediated control of pancreatic cancer growth and progressionR01CA186043 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2015 to 2019 · $95,085 awarded in 2019Same name and institution; not confirmed by an ID
- GPCRs: novel targets in cancer-associated fibroblastsR21CA189477 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2014 to 2015 · $168,563 awarded in 2015Same name and institution; not confirmed by an ID
- Targeting RON Receptor Signaling in Pancreatic CancerR21CA137692 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2009 to 2010 · $169,950 awarded in 2010Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:26 UTC. The ranking covers the 200 most relevant of 37 PubMed records, and a shared surname and initials can bring in a namesake. All 37 on PubMed
- 392 citationsRCR 14.1
- Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease.Ann Surg · 1997314 citationsRCR 12.4
- 306 citationsRCR 10.7
- Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial.JAMA Oncol · 2021266 citationsRCR 15.9
- Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer.Ann Surg · 1999225 citationsRCR 6.2
- 224 citationsRCR 11.1
- Long-chain acyl-CoA esters as indicators of lipid metabolism and insulin sensitivity in rat and human muscle.Am J Physiol Endocrinol Metab · 2000215 citationsRCR 5.0
- Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.Biol Psychiatry · 2007170 citationsRCR 6.0
- 148 citationsRCR 4.0
- 79 citationsRCR 2.3